18F-choline PET/CT physiological distribution and pitfalls in image interpretation: Experience in 80 patients with prostate cancer

Nuclear Medicine Communications

Volumn 31, Issue 1, 2010, Pages 39-45

  Schillaci, Orazio ^a   Calabria, Ferdinando ^a   Tavolozza, Mario ^a   Cicciò, Carmelo ^a   Carlani, Marco ^a   Caracciolo, Cristiana R ^a   Danieli, Roberta ^a   Orlacchio, Antonio ^a   Simonetti, Giovanni ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

18F choline; Abnormal uptake; Biodistribution; False positives; Pitfalls; Prostate cancer

Indexed keywords

CHOLINE; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROMETHYLCHOLINE;

ADULT; AGED; ARTICLE; BODY REGIONS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; LUNG NODULE; LYMPHADENOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MASTOIDITIS; MENINGIOMA; OTOMASTOIDITIS; PLEURISY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; THYROIDITIS; URINARY EXCRETION; BRAIN; COMPUTER ASSISTED DIAGNOSIS; INFLAMMATION; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; BRAIN; CHOLINE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFLAMMATION; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SOLITARY PULMONARY NODULE; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 74349124294     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328330adc5     Document Type: Article

References (17)

1. Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET/CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 2009; 53:245-268.
2. Reske SN, Blumstein NM, Glatting G. PET and PET/CT in relapsing prostate carcinoma. Urologe A 2006; 45:1240-1250. (Pubitemid 44623277)
3. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al.. Role of whole-body (18)F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008; 113:895-904.
4. Mercer JR. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential. J Pharm Pharm Sci 2007; 10:180-202.
5. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al.. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18-23.
6. Garcia JR, Soler M, Blanch MA, Ramirez I, Riera E, Lozano P, et al.. PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer. Rev Esp Med Nucl 2009; 28:95-100.
7. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36:73-92.
8. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004; 24:1411-1431.
9. Sureshbabu W, Mawlawi O. PET/CT imaging artefacts. J Nucl Med Technol 2005; 33:156-161.
10. Pieterman RM, Que TH, Elsinga PH, Pruim J, Van Putten JWG, Willemsen ATM, et al.. Comparison of 11C-choline and 18F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nuc Med 43:167-172.
11. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 37:420-428.
12. Liu Q, Peng ZM, Liu QW, Yao SZ, Zhang L, Meng L, et al.. The role of 11C-choline positron emission tomography-computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum. Chin Med J 2006; 119:634-639.
13. Wyss MT, Weber B, Honer M. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31:312-316.
14. Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur J Nucl Med Mol Imaging 2001; 28:1845-1849.
15. Cook GJ. Pitfalls in PET/CT interpretation. Q J Nucl Med Mol Imaging 2007; 3:235-243.
16. Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, et al.. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 2001; 28:1664-1670.
17. Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, Yamamoto Y, et al.. New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol 2008; 18:2901-2911.